Swiss drug maker Novartis (NVS) said its Phase III trial of Signifor LAR therapy was more effective in controlling acromegaly disease compared to other existing therapies. "These results strengthen ...
Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial Postmenopausal women who had surgical removal of ...
Acromegaly, a condition often linked with gigantism, occurs when the pituitary gland produces too much growth hormone (GH) after puberty leading to abnormal and excessive growth of the feet, hands and ...
ZURICH (Reuters) - Swiss drugmaker Novartis said on Monday a final-stage trial of its Signifor LAR therapy allowed for greater disease control in patients with the endocrine disorder acromegaly than ...
Circulating tumor DNA (ctDNA) during and after neoadjuvant chemotherapy and prior to surgery is a powerful prognostic factor in triple-negative breast cancer (TNBC). ADAPTcycle: Adjuvant dynamic ...
This was a 48-week, international, open-label, prospective trial of octreotide LAR. Eligible participants were aged 18–80 years with a biochemical diagnosis of acromegaly. Patients who had already ...
To compare changes in weight in obese patients who received long-acting octreotide (octreotide LAR) at one of three dose levels (20, 40, or 60 mg) or placebo over 6 months and to identify the lowest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback